Nicox Provides First Half 2025 Financial Results

Core Insights - Nicox SA reported its financial results for the first half of 2025, highlighting a significant decrease in revenue compared to the same period in 2024, primarily due to the sale of the VYZULTA royalty stream [5][9] - The company has secured over 12 months of operational runway and plans to fully repay its financial debts by 2026, aided by recent licensing payments [2][6] Financial Performance - Revenue for the first half of 2025 was €1.5 million, down from €6.1 million in the first half of 2024, reflecting a decrease in license payments and royalties [5] - Operating expenses decreased to €6.8 million from €10.1 million in the same period last year, mainly due to reduced payroll expenses [8] - The net loss for the first half of 2025 was €8.9 million, compared to a net loss of €4.3 million in the first half of 2024, which included a significant foreign exchange loss [9][10] Key Future Milestones - The company anticipates submitting New Drug Applications (NDA) for NCX 470 in the U.S. and China in 2026, with the Phase 3 clinical program in Japan already initiated [6][7] - Nicox's partners will handle the marketing authorization preparation and commercialization of NCX 470 in the global glaucoma market, valued at over $7 billion [2][4] Subsequent Events - In August and September 2025, Nicox received license payments totaling €12.5 million related to NCX 470 and clinical trial results, which will help reduce its financial debt of €7.4 million as of September 30, 2025 [4][11]